Download PDF
J Hand Microsurg 2022; 14(02): 113-120
DOI: 10.1055/s-0040-1709097
Original Article

Effect of Oral Prednisolone after Collagenase Injection for Dupuytren’s Contracture: A Randomized, Controlled Trial with a 1-Year Follow-Up

Yoshihiro Abe 
1   Department of Orthopedic Surgery, Chiba Rosai Hospital, Ichihara City, Japan
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Introduction This study verified the effectiveness of oral prednisolone after collagenase clostridium histolyticum (CCH) (10 mg/day for 2 weeks) for Dupuytren’s contracture with a 1-year follow-up.

Materials and Methods This study included 31 patients with a contracture of the metacarpophalangeal joint of ≥ 30 degrees. A total of 16 patients were allocated randomly to treatment with prednisolone and 15 patients were treated without prednisolone (control group).

Results At day 7, mean total active motion (TAM) was 235 degrees in the prednisolone group and 228 degrees in the control group. Mean Visual Analog Scale was 3.3 in the prednisolone group and 4.6 in the control group. There was significant difference between two groups. At day 30, mean TAM was 241 degrees in the prednisolone group and 233 degrees in the control group. There were significant difference between two groups The mean QuickDASH score was significantly higher in the control group (5.8 vs. 3.4). Recurrence was observed in 2/16 patients (13%) in the prednisolone group and 5/15 patients (33%) in the control group; there was no significant difference.

Conclusion The administration of prednisolone decreased the likelihood of adverse effects, and also improved finger flexion range of motion and reduced pain after CCH.

Keywords

Dupuytren’s contracture - collagenase injection - unité rhumatologique des affections de la main questionnaire - total active motion - visual analogue scale for pain - prednisolone - corticosteroid


Publication History

Article published online:
13 April 2020

© 2020. Society of Indian Hand Surgery & Microsurgeons. All rights reserved.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren’s contracture. J Hand Surg Am 2007; 32 (06) 767-774
    CrossrefPubMedGoogle Scholar
  • 2 Hurst LC, Badalamente MA, Hentz VR. et al CORD I Study Group. Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 2009; 361 (10) 968-979
    CrossrefPubMedGoogle Scholar
  • 3 Coleman S, Gilpin D, Tursi J, Kaufman G, Jones N, Cohen B. Multiple concurrent collagenase clostridium histolyticum injections to Dupuytren’s cords: an exploratory study. BMC Musculoskelet Disord 2012; 13: 61
    CrossrefPubMedGoogle Scholar
  • 4 Gaston RG, Larsen SE, Pess GM. et al The efficacy and safety of concurrent collagenase clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: a prospective. multicenter study. J Hand Surg Am 2015; 40 (10) 1963-1971
    CrossrefPubMedGoogle Scholar
  • 5 Cook J, Waughtel J, Andreoni AR, Sakharpe A, Friedman DW. Collagenase clostridium histolyticum for Dupuytren’s contracture: comparing single and concurrent injections. Plast Reconstr Surg 2019; 143 (04) 782e-787e
    CrossrefPubMedGoogle Scholar
  • 6 Sanjuan-Cerveró R, Carrera-Hueso FJ, Vazquez-Ferreiro P, Fikri-Benbrahim N, Franco-Ferrando N, Peimer CA. Pain associated with treatment of Dupuytren contracture with collagenase clostridium histolyticum. J Hand Surg Am 2017; 42 (02) e109-e114
    CrossrefPubMedGoogle Scholar
  • 7 United States FDA Report. Briefing document for collagenase Clostridium histolyticum (AA4500) in the treatment of advanced Dupuytren’s disease. Arthritis Advisory Committee Meeting, September 16, 2009. Available at: https://www.sec.gov/Archives/edgar/data/1182129/000119312509191187/dex991.htm Accessed June 9, 2019
    PubMed
  • 8 Dias JJ, Braybrooke J. Dupuytren’s contracture: an audit of the outcomes of surgery. J Hand Surg [Br] 2006; 31 (05) 514-521
    CrossrefPubMedGoogle Scholar
  • 9 Becker GW, Davis TR. The outcome of surgical treatments for primary Dupuytren’s disease—a systematic review. J Hand Surg Eur Vol 2010; 35 (08) 623-626
    CrossrefPubMedGoogle Scholar
  • 10 Peimer CA, Blazar P, Coleman S, Kaplan FT, Smith T, Lindau T. Dupuytren contracture recurrence following treatment with collagenase Clostridium histolyticum (CORDLESS [collagenase option for reduction of Dupuytren long-term evaluation of safety study]): 5-year data. J Hand Surg Am 2015; 40 (08) 1597-1605
    CrossrefPubMedGoogle Scholar
  • 11 The hand; examination, and diagnosis. American Society for Surgery of the Hand, 3rd ed. New York, USA: Churchill Livingstone 1990
  • 12 Beaudreuil J, Allard A, Zerkak D. et al URAM Study Group. Unité Rhumatologique des Affections de la Main (URAM) scale: development and validation of a tool to assess Dupuytren’s disease-specific disability. Arthritis Care Res (Hoboken) 2011; 63 (10) 1448-1455
    CrossrefPubMedGoogle Scholar
  • 13 Kershner P, Wang-Cheng R. Psychiatric side effects of steroid therapy. Psychosomatics 1989; 30 (02) 135-139
    CrossrefPubMedGoogle Scholar
  • 14 Peimer CA, Blazar P, Coleman S. et al Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS study): 3-year data. J Hand Surg Am 2013; 38 (01) 12-22
    CrossrefPubMedGoogle Scholar
  • 15 Ahmet A, Kim H, Spier S. Adrenal suppression: a practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy Asthma Clin Immunol 2011; 7 (01) 13-10
    CrossrefPubMedGoogle Scholar
  • 16 Liu D, Ahmet A, Ward L. et al A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013; 9 (01) 30
    CrossrefPubMedGoogle Scholar
  • 17 Kelly AM. Setting the benchmark for research in the management of acute pain in emergency departments. Emerg Med (Fremantle) 2001; 13 (01) 57-60
    CrossrefPubMedGoogle Scholar
  • 18 Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med 1996; 27 (04) 485-489
    Google Scholar
  • 19 Peimer CA, Wilbrand S, Gerber RA, Chapman D, Szczypa PP. Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur Vol 2015; 40 (02) 141-149
    CrossrefPubMedGoogle Scholar
  • 20 Witthaut J, Jones G, Skrepnik N, Kushner H, Houston A, Lindau TR. Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies. J Hand Surg Am 2013; 38 (01) 2-11
    CrossrefPubMedGoogle Scholar
  • 21 Schubert TEO, Weidler C, Borisch N, Schubert C, Hofstädter F, Straub RH. Dupuytren’s contracture is associated with sprouting of substance P positive nerve fibres and infiltration by mast cells. Ann Rheum Dis 2006; 65 (03) 414-415
    CrossrefPubMedGoogle Scholar
  • 22 Cole A, Emeighhart SG, Gerber R, Kaplan FT, Szczypa P. Collagénase de Clostridium histolyticum pour le traitement du flessum de Dupuytren: mécanisme d’action et effets tissulaires. Chir Main 2011; 30 (06) 468
    CrossrefPubMedGoogle Scholar
  • 23 Kaplan FT. Collagenase clostridium histolyticum injection for the treatment of Dupuytren’s contracture. Drugs Today (Barc) 2011; 47 (09) 653-667
    CrossrefPubMedGoogle Scholar
  • 24 National Institute for Health and Clinical Excellence (NICE). Clinical knowledge summaries: Corticosteroids - Oral. NICE; 2012. Available at: http://www.cks.nhs.uk/corticosteroids_oral. Accessed May 20, 2019
    PubMed
  • 25 Meek RMD, McLellan S, Reilly J, Crossan JF. The effect of steroids on Dupuytren’s disease: role of programmed cell death. J Hand Surg [Br] 2002; 27 (03) 270-273
    CrossrefPubMedGoogle Scholar
  • 26 Baird KS, Alwan WH, Crossan JF, Wojciak B. T-cell-mediated response in Dupuytren’s disease. Lancet 1993; 341 (88/61) 1622-1623
    CrossrefPubMedGoogle Scholar
  • 27 Qureshi FI, Hornigold R, Spencer JD, Hall SM. Langerhans cells in Dupuytren’s contracture. J Hand Surg [Br] 2001; 26 (04) 362-367
    CrossrefPubMedGoogle Scholar
  • 28 Meek RM, McLellan S, Crossan JF. Dupuytren’s disease. A model for the mechanism of fibrosis and its modulation by steroids. J Bone Joint Surg Br 1999; 81 (04) 732-738
    CrossrefPubMedGoogle Scholar
  • 29 Baird KS, Crossan JF, Ralston SH. Abnormal growth factor and cytokine expression in Dupuytren’s contracture. J Clin Pathol 1993; 46 (05) 425-428
    CrossrefPubMedGoogle Scholar
  • 30 Ketchum LD, Robinson DW, Masters FX. et al The degradation of mature collagen: a laboratory study. Plast Reconstr Surg 1967; 40 (01) 89-91
    CrossrefPubMedGoogle Scholar
  • 31 Ketchum LD, Donahue TK. The injection of nodules of Dupuytren’s disease with triamcinolone acetonide. J Hand Surg Am 2000; 25 (06) 1157-1162
    CrossrefPubMedGoogle Scholar